Development of Pandemic Vaccines: ERVEBO Case Study

Authors: Jayanthi Wolf, Risat Jannat, Sheri Dubey, Sean Troth, Matthew T. Onorato, Beth-Ann Coller, Mary E. Hanson, Jakub K. Simon

Source: Vaccines, Vol 9, Iss 3, p 190 (2021)

Subject Terms: Ebolavirus vaccine, rVSVΔG-ZEBOV-GP, vaccine development, regulatory strategy, vaccine manufacturing, Medicine

File Description: electronic resource

Relation: https://www.mdpi.com/2076-393X/9/3/190; https://doaj.org/toc/2076-393X

Access URL: https://doaj.org/article/94c5c7b69e2a4babbf8d53ab4442cb6a

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease

Authors: Joan G. Tell, Beth-Ann G. Coller, Sheri A. Dubey, Ursula Jenal, William Lapps, Liman Wang, Jayanthi Wolf

Source: Vaccines, Vol 8, Iss 4, p 779 (2020)

Subject Terms: ERA, rVSV, recombinant vaccine, GMO, vesicular stomatitis virus, Zaire ebolavirus, Medicine

File Description: electronic resource

Relation: https://www.mdpi.com/2076-393X/8/4/779; https://doaj.org/toc/2076-393X

Access URL: https://doaj.org/article/92d912a59d2e424c9fbd16f28e5bf387

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

Authors: Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, Richard Nichols, D. Gray Heppner, Jakub K. Simon, Sheri Dubey, Sean P. Troth, Jayanthi Wolf, Vidisha Singh, Beth-Ann Coller, James S. Robertson

Source: Vaccine: X, Vol 1, Iss , Pp - (2019)

Subject Terms: Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2590136219300105; https://doaj.org/toc/2590-1362

Access URL: https://doaj.org/article/b07b8cb0eee148b0870ad44a4db1f958